TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS

Increasing amounts of literature data suggest the leading role of indoleamine 2,3-deoxygenase (IDO) enzyme in regulation of immunosuppressive mechanisms. IDO is produced, mostly, by dendritic cells, being induced, e.g., under IFNγ involvement. Its function is to provide catabolism of tryptophan, an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	V. A. Kozlov, D. V. Demina
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2017
Materias:	immunopathology immunosuppression tryptophan indoleamine 2.3-dioxygenase kynurenine Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/b0dcc4ad92d94c48aafba6011501cf8a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b0dcc4ad92d94c48aafba6011501cf8a
record_format	dspace
spelling	oai:doaj.org-article:b0dcc4ad92d94c48aafba6011501cf8a2021-11-18T08:03:46ZTRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS1563-06252313-741X10.15789/1563-0625-2017-3-225-240https://doaj.org/article/b0dcc4ad92d94c48aafba6011501cf8a2017-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1257https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XIncreasing amounts of literature data suggest the leading role of indoleamine 2,3-deoxygenase (IDO) enzyme in regulation of immunosuppressive mechanisms. IDO is produced, mostly, by dendritic cells, being induced, e.g., under IFNγ involvement. Its function is to provide catabolism of tryptophan, an essential amino acid. Any reduction of tryptophan levels in extracellular environment was shown to cause functional suppression of certain immune cells, and induction of T regulatory cells. Accumulation of different tryptophan catabolites may exacerbate the immunosuppressive status induced by increased IDO expression. It is assumed that the interactions between IDO, tryptophan and its catabolites largely determine a development of hypersuppressor state in tumor growth and a hypo- (or lack of) suppressor status in autoimmune and allergic diseases. This implies some novel tasks for the therapy, including a treatment aimed for reduction of the IDO activity since the latter is involved in suppressor cell induction during tumor growth. Respectively, stimulation of IDO activity may augment suppressor activity of the regulatory cells.V. A. KozlovD. V. DeminaSPb RAACIarticleimmunopathologyimmunosuppressiontryptophanindoleamine 2.3-dioxygenasekynurenineImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 19, Iss 3, Pp 225-240 (2017)
institution	DOAJ
collection	DOAJ
language	RU
topic	immunopathology immunosuppression tryptophan indoleamine 2.3-dioxygenase kynurenine Immunologic diseases. Allergy RC581-607
spellingShingle	immunopathology immunosuppression tryptophan indoleamine 2.3-dioxygenase kynurenine Immunologic diseases. Allergy RC581-607 V. A. Kozlov D. V. Demina TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
description	Increasing amounts of literature data suggest the leading role of indoleamine 2,3-deoxygenase (IDO) enzyme in regulation of immunosuppressive mechanisms. IDO is produced, mostly, by dendritic cells, being induced, e.g., under IFNγ involvement. Its function is to provide catabolism of tryptophan, an essential amino acid. Any reduction of tryptophan levels in extracellular environment was shown to cause functional suppression of certain immune cells, and induction of T regulatory cells. Accumulation of different tryptophan catabolites may exacerbate the immunosuppressive status induced by increased IDO expression. It is assumed that the interactions between IDO, tryptophan and its catabolites largely determine a development of hypersuppressor state in tumor growth and a hypo- (or lack of) suppressor status in autoimmune and allergic diseases. This implies some novel tasks for the therapy, including a treatment aimed for reduction of the IDO activity since the latter is involved in suppressor cell induction during tumor growth. Respectively, stimulation of IDO activity may augment suppressor activity of the regulatory cells.
format	article
author	V. A. Kozlov D. V. Demina
author_facet	V. A. Kozlov D. V. Demina
author_sort	V. A. Kozlov
title	TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
title_short	TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
title_full	TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
title_fullStr	TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
title_full_unstemmed	TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
title_sort	tryptophan and indoleamine-2,3-dioxygenase (ido) in pathogenesis of immunosuppressive clinical conditions
publisher	SPb RAACI
publishDate	2017
url	https://doaj.org/article/b0dcc4ad92d94c48aafba6011501cf8a
work_keys_str_mv	AT vakozlov tryptophanandindoleamine23dioxygenaseidoinpathogenesisofimmunosuppressiveclinicalconditions AT dvdemina tryptophanandindoleamine23dioxygenaseidoinpathogenesisofimmunosuppressiveclinicalconditions
_version_	1718422372948639744

TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS

Ejemplares similares